Michael S Seaman

List of Publications by Year
in descending order

Version: 2024-02-01

187 papers	27,674 citations	9786 73 h-index	6471 157 g-index
200 all docs	200 docs citations	200 times ranked	20515 citing authors

#	Article	IF	Citations
1	Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters. Npj Vaccines, 2022, 7, 2.	6.0	2
2	Engineering panâ€“HIV-1 neutralization potency through multispecific antibody avidity. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	11
3	Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller. Journal of Experimental Medicine, 2022, 219, .	8.5	14
4	Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature, 2022, 606, 368-374.	27.8	75
5	Structural and functional impact by SARS-CoV-2 Omicron spike mutations. Cell Reports, 2022, 39, 110729.	6.4	102
6	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nature Medicine, 2022, 28, 1288-1296.	30.7	44
7	Combination anti-HIV antibodies provide sustained virological suppression. Nature, 2022, 606, 375-381.	27.8	65
8	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates. Journal of Virology, 2021, 95, .	3.4	18
9	A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. Nature Structural and Molecular Biology, 2021, 28, 202-209.	8.2	110
10	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1535.	7.4	260
11	Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. ELife, 2021, 10, .	6.0	16
12	Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus. Aids, 2021, 35, 1567-1574.	2.2	6
13	Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells. Cell Reports, 2021, 35, 109167.	6.4	8
14	Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement. Journal of Virology, 2021, 95, .	3.4	3
15	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. Science, 2021, 373, 642-648.	12.6	211
16	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. PLoS Pathogens, 2021, 17, e1009624.	4.7	2
17	Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera. Journal of Virology, 2021, 95, e0040421.	3.4	34
18	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell, 2021, 184, 3205-3221.e24.	28.9	73

#	Article	IF	Citations
19	Broadly Neutralizing Antibodies for HIV-1 Prevention. Frontiers in Immunology, 2021, 12, 712122.	4.8	43
20	Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell, 2021, 184, 4969-4980.e15.	28.9	94
21	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nature Medicine, 2021, 27, 1718-1724.	30.7	39
22	Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope. Npj Vaccines, 2021, 6, 126.	6.0	2
23	Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. Science, 2021, 374, 1353-1360.	12.6	246
24	Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees. Open Forum Infectious Diseases, 2021, 8, ofaa606.	0.9	2
25	Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Science Translational Medicine, 2021, 13, eabk1533.	12.4	27
26	Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity. Journal of Pharmaceutical Sciences, 2020, 109, 233-246.	3.3	9
27	Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs. Journal of Immunological Methods, 2020, 479, 112736.	1.4	9
28	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. Cell, 2020, 183, 185-196.e14.	28.9	25
29	Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. New England Journal of Medicine, 2020, 383, 2291-2293.	27.0	1,069
30	Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration. Antibodies, 2020, 9, 36.	2.5	7
31	Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent <scp>d</scp> -peptide HIV entry inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22436-22442.	7.1	15
32	Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. Cell, 2020, 183, 1496-1507.e16.	28.9	182
33	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infectious Diseases, The, 2020, 20, 1061-1070.	9.1	36
34	Structural basis of transmembrane coupling of the HIV-1 envelope glycoprotein. Nature Communications, 2020, 11, 2317.	12.8	49
35	Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. Journal of Virology, 2020, 94, .	3.4	5
36	Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity. Vaccine, 2020, 38, 3436-3446.	3.8	5

#	Article	IF	Citations
37	HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes. Nature Chemical Biology, 2020, 16, 529-537.	8.0	28
38	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. Cell, 2020, 180, 471-489.e22.	28.9	106
39	Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies. Nature Communications, 2020, 11, 3195.	12.8	15
40	Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies. PLoS Pathogens, 2020, 16, e1008083.	4.7	50
41	Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies. Journal of Immunological Methods, 2020, 479, 112764.	1.4	13
42	Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP) Tj ETQq0 0 0 rgBT /Overlock 10	4.0	19
43	Discovery of O-Linked Carbohydrate on HIV-1 Envelope and Its Role in Shielding against One Category of Broadly Neutralizing Antibodies. Cell Reports, 2020, 30, 1862-1869.e4.	6.4	25
44	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. Cell Host and Microbe, 2020, 27, 963-975.e5.	11.0	23
45	A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9981-9990.	7.1	51
46	Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic. JAMA Network Open, 2020, 3, e2030455.	5.9	315
47	Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection. Journal of Clinical Investigation, 2020, 130, 6429-6442.	8.2	7
48	A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. ELife, 2020, 9, .	6.0	10
49	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PLoS ONE, 2019, 14, e0219142.	2.5	58
50	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. Nature Communications, 2019, 10, 2898.	12.8	35
51	A microbial expression system for high-level production of scFv HIV-neutralizing antibody fragments in Escherichia coli. Applied Microbiology and Biotechnology, 2019, 103, 8875-8888.	3.6	9
52	Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. Cell Host and Microbe, 2019, 26, 623-637.e8.	11.0	56
53	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Immunity, 2019, 50, 1513-1529.e9.	14.3	85
54	Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature, 2019, 570, 468-473.	27.8	145

#	Article	IF	Citations
55	A Highly Unusual V1 Region of Env in an Elite Controller of HIV Infection. Journal of Virology, 2019, 93, .	3.4	14
56	HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells. Journal of Experimental Medicine, 2019, 216, 1301-1310.	8.5	80
57	Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization. Cell Reports, 2019, 29, 3060-3072.e7.	6.4	26
58	Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. Journal of Virology, 2019, 93, .	3.4	25
59	Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. Journal of Virology, 2019, 93, .	3.4	13
60	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host and Microbe, 2019, 25, 59-72.e8.	11.0	124
61	Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. JCI Insight, 2019, 4, .	5.0	25
62	A single injection of crystallizable fragment domainâ€“modified antibodies elicits durable protection from SHIV infection. Nature Medicine, 2018, 24, 610-616.	30.7	94
63	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. Journal of Infectious Diseases, 2018, 218, 633-644.	4.0	35
64	Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized Mice. Journal of Virology, 2018, 92, .	3.4	24
65	Neutralization tiers of HIV-1. Current Opinion in HIV and AIDS, 2018, 13, 128-136.	3.8	89
66	Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses. Cell, 2018, 173, 1783-1795.e14.	28.9	80
67	Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. Journal of Virology, 2018, 92, .	3.4	10
68	TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. Science Translational Medicine, 2018, 10, .	12.4	133
69	Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet, The, 2018, 391, 563-571.	13.7	165
70	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. Journal of Virology, 2018, 92, .	3.4	39
71	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature, 2018, 561, 479-484.	27.8	392
72	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nature Medicine, 2018, 24, 1701-1707.	30.7	195

#	Article	IF	Citations
73	Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies. Journal of Pharmaceutical Sciences, 2018, 107, 3032-3046.	3.3	18
74	Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. Cell Reports, 2018, 25, 893-908.e7.	6.4	91
75	Structure of the membrane proximal external region of HIV-1 envelope glycoprotein. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8892-E8899.	7.1	72
76	Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity. Cell Reports, 2018, 23, 2568-2581.	6.4	46
77	Relationship between latent and rebound viruses in a clinical trial of antiâ€“HIV-1 antibody 3BNC117. Journal of Experimental Medicine, 2018, 215, 2311-2324.	8.5	84
78	Tâ€cell subset differentiation and antibody responses following antiretroviral therapy during simian immunodeficiency virus infection. Immunology, 2018, 155, 458-466.	4.4	1
79	Exploiting glycan topography for computational design of Env glycoprotein antigenicity. PLoS Computational Biology, 2018, 14, e1006093.	3.2	19
80	Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys. Journal of Virology, 2018, 92, .	3.4	9
81	Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathogens, 2018, 14, e1006860.	4.7	68
82	Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. JCI Insight, 2018, 3, .	5.0	16
83	Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Science Translational Medicine, 2017, 9, .	12.4	128
84	Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nature Medicine, 2017, 23, 185-191.	30.7	399
85	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Science Immunology, 2017, 2, .	11.9	119
86	HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. Journal of Virology, 2017, 91, .	3.4	26
87	Antigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4477-4482.	7.1	18
88	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. Journal of Virology, 2017, 91, .	3.4	40
89	Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nature Communications, 2017, 8, 15740.	12.8	11
90	Early antibody therapy can induce long-lasting immunity to SHIV. Nature, 2017, 543, 559-563.	27.8	244

#	Article	IF	Citations
91	Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens. Vaccine, 2017, 35, 1-9.	3.8	14
92	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Science Translational Medicine, 2017, 9, .	12.4	106
93	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science Translational Medicine, 2017, 9, .	12.4	87
94	Non-neutralizing Antibodies Alter the Course of HIV-1 Infection InÂVivo. Cell, 2017, 170, 637-648.e10.	28.9	111
95	Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. Journal of Virology, 2017, 91, .	3.4	23
96	An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 2017, 547, 217-221.	27.8	2,112
97	Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV. Clinical Infectious Diseases, 2017, 64, 1098-1104.	5.8	36
98	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathogens, 2017, 13, e1006182.	4.7	38
99	Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. ELife, 2017, 6, .	6.0	52
100	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathogens, 2016, 12, e1005520.	4.7	150
101	Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nature Communications, 2016, 7, 10618.	12.8	166
102	Transient CD4⁺T Cell Depletion Results in Delayed Development of Functional Vaccine-Elicited Antibody Responses. Journal of Virology, 2016, 90, 4278-4288.	3.4	13
103	HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science, 2016, 352, 997-1001.	12.6	263
104	Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7908-E7916.	7.1	164
105	Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nature Structural and Molecular Biology, 2016, 23, 906-915.	8.2	188
106	Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. Journal of Virology, 2016, 90, 10362-10378.	3.4	26
107	Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity, 2016, 45, 1108-1121.	14.3	304
108	Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. Cell, 2016, 165, 1609-1620.	28.9	130

#	Article	IF	Citations
109	Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity. Cell, 2016, 165, 1621-1631.	28.9	157
110	HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature, 2016, 535, 556-560.	27.8	400
111	Structural basis for membrane anchoring of HIV-1 envelope spike. Science, 2016, 353, 172-175.	12.6	169
112	Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy. Open Forum Infectious Diseases, 2016, 3, ofw100.	0.9	14
113	Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry Inhibition. ACS Medicinal Chemistry Letters, 2016, 7, 330-334.	2.8	86
114	HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4 ⁺ T Cell Responses. Journal of Virology, 2016, 90, 2208-2220.	3.4	29
115	Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity. Journal of Virology, 2016, 90, 636-649.	3.4	70
116	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. Journal of Virology, 2016, 90, 4133-4149.	3.4	22
117	Î» Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies. Journal of Infectious Diseases, 2016, 213, 156-164.	4.0	18
118	Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences. PLoS Pathogens, 2016, 12, e1005431.	4.7	18
119	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathogens, 2016, 12, e1005742.	4.7	81
120	Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. PLoS Pathogens, 2015, 11, e1005110.	4.7	78
121	A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. PLoS Pathogens, 2015, 11, e1005238.	4.7	43
122	A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site. Molecular Immunology, 2015, 66, 364-374.	2.2	30
123	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. Journal of Virology, 2015, 89, 6462-6480.	3.4	40
124	AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature, 2015, 519, 87-91.	27.8	265
125	Intra-Spike Crosslinking Overcomes Antibody Evasion by HIV-1. Cell, 2015, 160, 433-446.	28.9	109
126	HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science, 2015, 349, aac4223.	12.6	482

#	Article	IF	Citations
127	Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. Science, 2015, 349, 191-195.	12.6	113
128	Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL. Journal of Virology, 2015, 89, 9090-9102.	3.4	10
129	Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C. AIDS Research and Human Retroviruses, 2015, 31, 1192-1201.	1.1	5
130	Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell, 2015, 161, 1505-1515.	28.9	239
131	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science, 2015, 349, 320-324.	12.6	303
132	Induction of HIV-1â€“Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of Humans. Journal of Infectious Diseases, 2015, 211, 518-528.	4.0	60
133	Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature, 2015, 522, 487-491.	27.8	665
134	Generation and Evaluation of Clade C Simian-Human Immunodeficiency Virus Challenge Stocks. Journal of Virology, 2015, 89, 1965-1974.	3.4	28
135	A Multivalent Clade C HIV-1 Env Trimer Cocktail Elicits a Higher Magnitude of Neutralizing Antibodies than Any Individual Component. Journal of Virology, 2015, 89, 2507-2519.	3.4	42
136	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. Journal of Virology, 2015, 89, 8525-8539.	3.4	35
137	Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. Virology, 2015, 475, 37-45.	2.4	25
138	Characterization and Immunogenicity of a Novel Mosaic M HIV-1 gp140 Trimer. Journal of Virology, 2014, 88, 9538-9552.	3.4	30
139	Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV. Science Translational Medicine, 2014, 6, 236ra63.	12.4	160
140	Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17624-17629.	7.1	324
141	Molecular Evolution of Broadly Neutralizing Llama Antibodies to the CD4-Binding Site of HIV-1. PLoS Pathogens, 2014, 10, e1004552.	4.7	34
142	Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. Journal of Experimental Medicine, 2014, 211, 2361-2372.	8.5	79
143	Rational Design and Characterization of the Novel, Broad and Potent Bispecific HIV-1 Neutralizing Antibody iMabm36. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 473-483.	2.1	40
144	Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers. Immunity, 2014, 40, 657-668.	14.3	342

#	Article	IF	Citations
145	Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. Journal of Immunological Methods, 2014, 409, 131-146.	1.4	435
146	Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. Vaccine, 2014, 32, 2109-2116.	3.8	27
147	Enhanced Immunogenicity of an HIV-1 DNA Vaccine Delivered with Electroporation via Combined Intramuscular and Intradermal Routes. Journal of Virology, 2014, 88, 6959-6969.	3.4	32
148	Disruption of Helix-Capping Residues 671 and 674 Reveals a Role in HIV-1 Entry for a Specialized Hinge Segment of the Membrane Proximal External Region of gp41. Journal of Molecular Biology, 2014, 426, 1095-1108.	4.2	34
149	Investigating Broad Neutralization in HIV-1 Non-B Subtype Infection in YaoundÃ©, Cameroon. AIDS Research and Human Retroviruses, 2014, 30, A152-A152.	1.1	0
150	Topology Influences V2 Epitope Focusing. AIDS Research and Human Retroviruses, 2014, 30, A193-A193.	1.1	0
151	Common Features of Mucosal and Peripheral Antibody Responses Elicited by Candidate HIV-1 Vaccines in Rhesus Monkeys. Journal of Virology, 2014, 88, 13510-13515.	3.4	5
152	Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. Journal of Virology, 2014, 88, 2489-2507.	3.4	274
153	A Fusion Intermediate gp41 Immunogen Elicits Neutralizing Antibodies to HIV-1. Journal of Biological Chemistry, 2014, 289, 29912-29926.	3.4	32
154	Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice. Cell, 2014, 158, 989-999.	28.9	337
155	Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for InÂVivo Activity. Cell, 2014, 158, 1243-1253.	28.9	419
156	Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies. Journal of Virology, 2014, 88, 12623-12643.	3.4	75
157	Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike. Cell Reports, 2014, 7, 785-795.	6.4	199
158	Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. Aids, 2014, 28, 163-169.	2.2	334
159	HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16538-16543.	7.1	247
160	Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature, 2013, 503, 224-228.	27.8	593
161	Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature, 2013, 503, 277-280.	27.8	424
162	Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys. Cell, 2013, 155, 531-539.	28.9	334

#	Article	IF	Citations
163	Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization. Cell, 2013, 153, 126-138.	28.9	478
164	Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13540-13545.	7.1	73
165	A mouse model for HIV-1 entry. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15859-15864.	7.1	75
166	Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. Journal of Experimental Medicine, 2012, 209, 1091-1103.	8.5	91
167	HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes. Journal of Virology, 2012, 86, 3393-3397.	3.4	71
168	Complex-type N -glycan recognition by potent broadly neutralizing HIV antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3268-77.	7.1	505
169	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature, 2012, 492, 118-122.	27.8	463
170	Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature, 2012, 482, 89-93.	27.8	452
171	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. Journal of Experimental Medicine, 2012, 209, 1469-1479.	8.5	156
172	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. Journal of Virology, 2011, 85, 9998-10009.	3.4	393
173	Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. Science, 2011, 333, 1633-1637.	12.6	1,046
174	Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses. PLoS ONE, 2011, 6, e24078.	2.5	99
175	Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design. Science, 2011, 334, 1289-1293.	12.6	345
176	Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Science Translational Medicine, 2011, 3, 81ra36.	12.4	179
177	Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature, 2010, 467, 591-595.	27.8	393
178	Effect of Vaccination with Modified Vaccinia Ankara (ACAM3000) on Subsequent Challenge with Dryvax. Journal of Infectious Diseases, 2010, 201, 1353-1360.	4.0	35
179	Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies. PLoS Computational Biology, 2010, 6, e1000955.	3.2	78
180	Breadth of Neutralizing Antibodies Elicited by Stable, Homogeneous Clade A and Clade C HIV-1 gp140 Envelope Trimers in Guinea Pigs. Journal of Virology, 2010, 84, 3270-3279.	3.4	89

#	Article	IF	Citations
181	Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science, 2010, 329, 856-861.	12.6	1,600
182	Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies. Journal of Virology, 2010, 84, 1439-1452.	3.4	589
183	Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature, 2009, 458, 636-640.	27.8	806
184	Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology, 2007, 367, 175-186.	2.4	37
185	Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys. Journal of Virology, 2005, 79, 2956-2963.	3.4	120
186	Vaccine-Elicited Memory Cytotoxic T Lymphocytes Contribute to Mamu-A*01-Associated Control of Simian/Human Immunodeficiency Virus 89.6P Replication in Rhesus Monkeys. Journal of Virology, 2005, 79, 4580-4588.	3.4	27
187	Subsets of Memory Cytotoxic T Lymphocytes Elicited by Vaccination Influence the Efficiency of Secondary Expansion In Vivo. Journal of Virology, 2004, 78, 206-215.	3.4	50